Royalty Pharma Plc Quick Ratio (RPRX) starting from the second quarter 2026 to second quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Royalty Pharma Plc  (NASDAQ: RPRX)

Royalty Pharma Plc's Quick Ratio

RPRX's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Royalty Pharma Plc's Cash & cash equivalent grew by 37.6 % in the Q2 2026 sequentially, faster than Current Liabilities, this led to improvement in Royalty Pharma Plc's Quick Ratio to 1.33, Quick Ratio remained below Royalty Pharma Plc average.

Within Major Pharmaceutical Preparations industry 327 other companies have achieved higher Quick Ratio than Royalty Pharma Plc in second quarter 2026. While Quick Ratio total ranking in the second quarter 2026 has deteriorated compared to the prior quarter from 1581 to 1731.

Explain Quick Ratio?
How much Cash & cash equivalents RPRX´s has?
What are RPRX´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

RPRX Quick Ratio (Jun 30 2026)
Q2		 (Mar 31 2026)
Q1		 (Dec 31 2025)
Q4		 (Sep 30 2025)
Q3		 (Jun 30 2025)
Q2
Y / Y Current Liabilities Change -42.92 % -54.71 % -45.98 % -51.24 % 523.87 %
Y / Y Cash & cash equivalent Change -28.47 % -44.69 % -35.43 % -4.36 % -35.11 %
Quick Ratio MRQ 1.33 1.14 1 1.8 1.06
RPRX's Total Ranking # 1731 # 1581 # 287 # 348 #
Seq. Current Liabilities Change 17.78 % -15.8 % 19.86 % -51.97 % -6.56 %
Seq. Cash & cash equivalent Change 37.6 % -4.58 % -33.25 % -18.38 % 6.39 %



Quick Ratio second quarter 2026 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 328
Healthcare Sector # 583
Overall Market # 1731


Quick Ratio Statistics
High Average Low
35.91 8.89 0.84
(Sep 30 2023)   (Dec 31 2024)




Financial Statements
Royalty Pharma Plc's Current Liabilities $ 631 Millions Visit RPRX's Balance sheet
Royalty Pharma Plc's Cash & cash equivalent $ 837 Millions Visit RPRX's Balance sheet
Source of RPRX's Sales Visit RPRX's Sales by Geography


Cumulative Royalty Pharma Plc's Quick Ratio

RPRX's Quick Ratio for the trailling 12 Months

RPRX Quick Ratio

 (Jun 30 2026)
12 Months		 (Mar 31 2026)
12 Months		 (Dec 31 2025)
12 Months		 (Sep 30 2025)
12 Months		 (Jun 30 2025)
12 Months
Y / Y Current Liabilities TTM Growth -48.76 % -22.57 % 39.5 % 190.21 % 1346.94 %
Y / Y Cash & cash equivalent TTM Growth -28.62 % -31.05 % -17.13 % 1.04 % 3.49 %
Quick Ratio TTM 1.3 1.2 1.12 1.05 0.93
Total Ranking TTM # 3913 # 3145 # 752 # 3018 #
Seq. Current Liabilities TTM Growth -16.89 % -18.73 % -13.55 % -12.25 % 25.59 %
Seq. Cash & cash equivalent TTM Growth -9.88 % -12.73 % -8.3 % -1.02 % -12.95 %

Quick ratio ranking by company, industry and sector >> Back to RPRX Financial Strength Comparisons >> Go to Compare RPRX Quick Ratio to its Competitors

On the trailing twelve months basis Current Liabilities decreased faster than Royalty Pharma Plc's average Cash & cash equivalent, this led to increase in in Royalty Pharma Plc's Quick Ratio to 1.3, Quick Ratio remained below RPRX average.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 433 other companies have achieved higher Quick Ratio than Royalty Pharma Plc. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the first quarter 2026 from 3145 to 3913.

Explain Quick Ratio?
How much Cash & cash equivalents RPRX´s has?
What are RPRX´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 434
Healthcare Sector # 888
Within the Market # 3913


trailing twelve months Quick Ratio Statistics
High Average Low
21.45 7.17 0.75
(Mar 31 2014)   (Jun 30 2025)




Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Major Pharmaceutical Preparations Industry Quick RatioJun 30 2026 MRQ Cash & cash equivalentJun 30 2026 MRQ Current Liabilities
Aptevo Therapeutics Inc   3.47 $ 17.997  Millions$ 5.188  Millions
Ataibeckley Inc   3.43 $ 168.807  Millions$ 49.221  Millions
Dogwood Therapeutics inc   3.40 $ 9.628  Millions$ 2.831  Millions
Tvardi Therapeutics Inc   3.39 $ 30.865  Millions$ 9.113  Millions
Biomea Fusion Inc   3.32 $ 34.824  Millions$ 10.483  Millions
Abeona Therapeutics Inc   3.32 $ 146.826  Millions$ 44.233  Millions
Foghorn Therapeutics Inc   3.31 $ 167.582  Millions$ 50.579  Millions
Cingulate Inc   3.29 $ 28.403  Millions$ 8.631  Millions
Unicycive Therapeutics Inc  3.28 $ 61.425  Millions$ 18.704  Millions
Harmony Biosciences Holdings inc   3.17 $ 667.791  Millions$ 210.812  Millions
Pulmatrix Inc   3.15 $ 2.168  Millions$ 0.689  Millions
Nextcure Inc   3.13 $ 20.088  Millions$ 6.413  Millions
Dianthus Therapeutics Inc   3.13 $ 107.611  Millions$ 34.389  Millions
Tg Therapeutics Inc   3.02 $ 811.665  Millions$ 268.493  Millions
Dermata Therapeutics Inc   3.02 $ 4.413  Millions$ 1.462  Millions
Xilio Therapeutics Inc   2.99 $ 136.040  Millions$ 45.487  Millions
Cadrenal Therapeutics Inc  2.99 $ 4.476  Millions$ 1.497  Millions
Zevra Therapeutics Inc   2.99 $ 145.321  Millions$ 48.632  Millions
Inhibitor Therapeutics Inc   2.95 $ 0.516  Millions$ 0.175  Millions
Annovis Bio Inc   2.95 $ 18.736  Millions$ 6.359  Millions
Puma Biotechnology Inc   2.89 $ 144.164  Millions$ 49.825  Millions
Ptc Therapeutics inc   2.89 $ 2,229.082  Millions$ 771.068  Millions
Werewolf Therapeutics Inc   2.80 $ 21.987  Millions$ 7.863  Millions
Alzamend Neuro Inc   2.77 $ 7.591  Millions$ 2.739  Millions
Scienture Holdings Inc   2.71 $ 8.188  Millions$ 3.026  Millions
Acadia Pharmaceuticals Inc   2.65 $ 956.474  Millions$ 361.436  Millions
Edesa Biotech Inc   2.63 $ 10.300  Millions$ 3.910  Millions
Hepion Pharmaceuticals Inc   2.63 $ 1.629  Millions$ 0.620  Millions
Stoke Therapeutics Inc   2.62 $ 110.004  Millions$ 41.930  Millions
Elicio Therapeutics Inc   2.55 $ 23.480  Millions$ 9.202  Millions

Date modified: 2026-09-08T15:11:45+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.